Discovery of IHMT-MST1-58 as a Novel, Potent, and Selective MST1 Inhibitor for the Treatment of Type 1/2 Diabetes by Yun Wu (150224)

Subjects:

Decreased peritumoral myofibroblasts in the MC38 S.C. tumors of <i>S100a4-Cre; Ext1</i>^<i>f/f</i> mice. by Ayumi Niwa (6256790)

TG6-44 treatment leads to a decrease in NP-positive cells and altered expression patterns of NP in A/X31 infected THP-1 cells. by Juan A. De La Cruz (11154187)

<i>crh-1</i> mutants exhibit a decrease of <i>daf-7</i> expression in the ASI neurons. by JiSoo Park (11133976)

Hematopoietic-restricted loss of Zeb1 decreases hematopoietic colony formation potential and ability to compete with wt HSPCs for contribution to all hematopoietic lineages. by Jueqiong Wang (11467505)

“…<b>(C)</b> <i>Zeb1</i> null (Vav-iCre, <i>Zeb1</i>^fl/fl) CD45.2⁺ donor cells (orange bars) were outcompeted by control CD45.1⁺ competitor HSPCs (blue bars) for their ability to contribute to all hematopoietic cells analyzed in the PB and BM (rightmost panels). …”

The C-terminus of Ssa2 is required for HU resistance. by Laura E. Knighton (5991239)

Discovery of Triazolyl Derivatives of Cucurbitacin B Targeting IGF2BP1 against Non-Small Cell Lung Cancer by Fan-Fan Shang (16953264)

Subjects:

Dose response of airways to Methacholine shows a decreased contractility in <i>GSTCD</i>^-/- mouse lungs following LPS treatment. by Bo Liu (127343)

Skp2 inhibitor SKPin C1 decreased viability and proliferation of multiple myeloma cells and induced apoptosis by Ying Yang (24175)

“…In contrast, 50 μM SKPin C1 only marginally decreased viability of normal B lymphocytes in 12 h. …”

The GluN2B-C456Y mutation decreases recombinant NMDAR currents and alters receptor properties. by Wangyong Shin (6793040)

Subjects:

Single and sequential wavelength disinfection kinetics for flow through UV experiments using LP 254 nm and LED 285 nm reactors. by Daniel Ma (12698752)

Subjects:

<i>clec-4(ok2050)</i> and <i>clec-4(ya1)</i> decrease <i>C</i>. <i>elegans</i> feeding leading to a reduced bacterial load. by Barbara Pees (3313560)

Data_Sheet_1_Microclimatic Warming Leads to a Decrease in Species and Growth Form Diversity: Insights From a Tropical Alpine Grassland.PDF by Sisimac A. Duchicela (11503918)

“…The increase of tussocks led to a significant decrease in species diversity and evenness inside OTCs, but not in species richness after accounting by sampling time. …”

UPLC-DAD profile (270 nm) of phytocannabinoids in the extracts separated in C18 column. by Bruno Musetti (9527085)

Stress strain curves (from a1 to f1), stress—AE count plots (from a2 to f2) and stress—cumulative AE count plots (from a3 to f3) for the sample temperatures of 20°C, 50°C, 100°C, 1... by Nazlı Tunar Özcan (14833635)

Discovery of a Trifluoromethoxy Cyclopentanone Benzothiazole Receptor-Interacting Protein Kinase 1 Inhibitor as the Treatment for Alzheimer’s Disease by Yi Sun (118759)

“…<b>SZM679</b>, a highly specific RIPK1 inhibitor (<i>K</i>_d,RIPK1 = 8.6 nM, <i>K</i>_d,RIPK3 > 5000 nM), was developed by our group with superior high antinecroptotic activity (EC₅₀ = 2 nM), and investigated to completely reverse the tumor necrosis factor-induced systemic inflammatory response syndrome. …”

Discovery of a Trifluoromethoxy Cyclopentanone Benzothiazole Receptor-Interacting Protein Kinase 1 Inhibitor as the Treatment for Alzheimer’s Disease by Yi Sun (118759)

“…<b>SZM679</b>, a highly specific RIPK1 inhibitor (<i>K</i>_d,RIPK1 = 8.6 nM, <i>K</i>_d,RIPK3 > 5000 nM), was developed by our group with superior high antinecroptotic activity (EC₅₀ = 2 nM), and investigated to completely reverse the tumor necrosis factor-induced systemic inflammatory response syndrome. …”

Discovery of a Trifluoromethoxy Cyclopentanone Benzothiazole Receptor-Interacting Protein Kinase 1 Inhibitor as the Treatment for Alzheimer’s Disease by Yi Sun (118759)

“…<b>SZM679</b>, a highly specific RIPK1 inhibitor (<i>K</i>_d,RIPK1 = 8.6 nM, <i>K</i>_d,RIPK3 > 5000 nM), was developed by our group with superior high antinecroptotic activity (EC₅₀ = 2 nM), and investigated to completely reverse the tumor necrosis factor-induced systemic inflammatory response syndrome. …”

Discovery of a Trifluoromethoxy Cyclopentanone Benzothiazole Receptor-Interacting Protein Kinase 1 Inhibitor as the Treatment for Alzheimer’s Disease by Yi Sun (118759)

“…<b>SZM679</b>, a highly specific RIPK1 inhibitor (<i>K</i>_d,RIPK1 = 8.6 nM, <i>K</i>_d,RIPK3 > 5000 nM), was developed by our group with superior high antinecroptotic activity (EC₅₀ = 2 nM), and investigated to completely reverse the tumor necrosis factor-induced systemic inflammatory response syndrome. …”

Discovery of a Trifluoromethoxy Cyclopentanone Benzothiazole Receptor-Interacting Protein Kinase 1 Inhibitor as the Treatment for Alzheimer’s Disease by Yi Sun (118759)

“…<b>SZM679</b>, a highly specific RIPK1 inhibitor (<i>K</i>_d,RIPK1 = 8.6 nM, <i>K</i>_d,RIPK3 > 5000 nM), was developed by our group with superior high antinecroptotic activity (EC₅₀ = 2 nM), and investigated to completely reverse the tumor necrosis factor-induced systemic inflammatory response syndrome. …”